MedTrace Logo

A Randomized Controlled Trial of Lamivudine in Acute Hepatitis B

NCT00380614 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2006-09-26

No results posted yet for this study

Summary

Since a proportion of patients with Acute Viral Hepatitis-B develop severe hepatitis and fulminant hepatic failure, it is logical to believe that a rapid reduction in the HBV DNA levels by using antiviral agents could result in a less intense host response against the hepatitis B virus. However, the experience with lamivudine treatment of immunocompetent patients with AVH-B is limited.The aim of the present study was to evaluate the efficacy, utility and safety of lamivudine in treating immunocompetent patients with AVH-B.

Conditions

Interventions

DRUG

Lamivudine

Sponsors & Collaborators

  • Maulana Azad Medical College

    lead OTHER

Principal Investigators

  • Shiv K Sarin, MD, DM · G.B. Pant Hospital, New Delhi, India

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
5 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-01-31
Completion
2005-03-31

Countries

  • India

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00380614 on ClinicalTrials.gov